Zanzalintinib (XL092)

Name: Zanzalintinib (XL092) in Metastatic colorectal cancer: Pharmacodynamics
Published: 2026-09-14T15:39:06-04:00

Metastatic colorectal cancer

Manufacturer: Exelixis
Regulatory submission: NDA submitted December 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Pharmacology

Pharmacodynamics

2 evidence topics · 2 sources

Preclinical macrophage findings

“XL092 promoted M2 to M1 repolarization of macrophages in vitro and inhibited primary human macrophage efferocytosis in a dose-dependent manner.” (opens the source at this quote in a new tab)

Preclinical VEGFR2 phosphorylation in murine lungs

“a 96% inhibition of VEGFR2 phosphorylation in murine lungs.” (opens the source at this quote in a new tab)